Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LillyTrials.com Unveils Five Ongoing Studies For Cymbalta

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase IV Cymbalta studies include trial of patients who switched from other antidepressants. Lilly expects all eligible trials will be posted on the website within six months.

You may also be interested in...



Prozac Documents Deemed "Missing" Were Already Available, Lilly Says

The documents which appeared in the British Medical Journal were shared with FDA, published in medical journals or produced through legal discovery over 10 years ago, Lilly says. The company maintains the medical journal "published data without validating the information."

Prozac Documents Deemed "Missing" Were Already Available, Lilly Says

The documents which appeared in the British Medical Journal were shared with FDA, published in medical journals or produced through legal discovery over 10 years ago, Lilly says. The company maintains the medical journal "published data without validating the information."

“Missing” Lilly Documents Under Review By Rep. Hinchey

The documents allegedly suggest that Lilly was aware of a link between Prozac and suicidality as early as the 1980s. Hinchey is expected to issue a statement regarding the documents by Jan. 7.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel